GlassScriptPhysician profile
Danilo A Enriquez
NPI 1619947066
$1,917.58
in general payments reported to CMS, 2019-2025
18 companies · $216 in 2025
The $216 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $265 · 2020: $152 · 2021: $318 · 2022: $291 · 2023: $449 · 2024: $226 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $791 · Education: $99.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $791.39 |
| Education | $99.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $471.11 | 2019-2025 | Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.52 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $218.04 | 2020-2022 | |
| Actelion Pharmaceuticals US, INC. | $172.40 | 2023 | Uptravi, Opsumit |
| Genentech USA, INC. | $140.75 | 2019 | |
| Abbvie INC. | $118.42 | 2021-2025 | |
| Intuitive Surgical, INC. | $100.00 | 2024 | |
| Insmed, INC. | $92.31 | 2019-2021 | |
| Pfizer INC. | $40.75 | 2021 | |
| Mallinckrodt Hospital Products INC. | $37.23 | 2024 | Acthar |
| Merck Sharp & Dohme LLC | $36.87 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $34.68 | 2023 | Dupixent |
| Gilead Sciences, INC. | $33.12 | 2021-2022 | |
| Mylan Specialty L.P. | $28.21 | 2024 | Yupelri |
| Harmony Biosciences LLC | $26.60 | 2023 | Wakix |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $23.42 | 2023 | Tezspire |
| Inogen, INC. | $20.84 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Glaxosmithkline, LLC. | $20.31 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danilo Enriquez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.